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Summary
 
The 
 
a
 
/
 
b
 
 T cell receptor (TCR) recognizes peptide fragments bound in the groove of major
histocompatibility complex (MHC) molecules. We modified the TCR 
 
a
 
 chain from a mouse
T cell hybridoma and tested its ability to reconstitute TCR expression and function in an 
 
a
 
chain–deficient variant of the hybridoma. The modified 
 
a
 
 chain differed from wild type only
in its leader peptide and mature NH
 
2
 
-terminal amino acid. Reconstituted cell surface TCR
complexes reacted normally with anti-TCR and anti-CD3 antibodies. Although cross-linking
of this TCR with an antibody to the TCR idiotype elicited vigorous T cell hybridoma activa-
tion, stimulation with its natural MHC 
 
1
 
 peptide ligand did not. We demonstrated that this
phenotype could be reproduced simply by substituting the glutamic acid (E) at the mature NH
 
2
 
terminus of the wild type TCR 
 
a
 
 chain with aspartic acid (D). The substitution also dramati-
cally reduced the affinity of soluble 
 
a
 
/
 
b
 
-TCR heterodimers for soluble MHC 
 
1
 
 peptide mol-
ecules in a cell-free system, suggesting that it did not exert its effect simply by disrupting TCR
interactions with accessory molecules on the hybridoma. These results demonstrate for the first
time that amino acids which are not in the canonical TCR complementarity determining re-
gions can be critical in determining how the TCR engages MHC 
 
1
 
 peptide.
 
T
 
he structural basis of antigen recognition by antibody
molecules has been intensely studied using x-ray crys-
tallography. Crystal structures of a large array of antibodies
and antibody–antigen complexes have demonstrated that the
hypervariable regions of Ig genes encode solvent-exposed
loops that cluster to form the antigen-binding site of the Ig
V domains. These loops are known as CDRs. Analysis of
Ig crystal structures and CDR sequences has shown that the
spatial orientation and conformation of the loops is influ-
enced by two factors.
The first concerns the CDR itself. Each of the CDR
loops appears to adopt a limited range of main chain con-
formations despite their diverse amino acid sequences (1).
These conformations are shaped by a small number of rela-
tively well-conserved amino acid residues within the loops.
The second factor is the V domain scaffolding upon which
the CDRs rest. It consists of two 
 
b
 
 sheets packed face to
face and anchored by a structurally conserved core of “frame-
work” residues. The conformations of CDR loops are par-
tially determined by the manner in which they pack with
the side chains of certain framework residues (1, 2). An un-
derstanding of these factors has resulted in a limited ability
to predict CDR loop conformations of Igs of unknown
crystal structure from the sequences of their heavy and light
chain genes (1). This is a first step towards the engineering
of antibodies specific for antigens of interest.
The 
 
a
 
/
 
b
 
-TCR recognizes peptide fragments bound in
the groove of MHC molecules. The structural basis of this
recognition is understood in far less detail than that for Igs,
largely because soluble versions of these naturally mem-
brane-bound structures have only recently been developed.
Crystal structures of MHC class I (3–7) and class II (8–10)
molecules with single peptides bound in their grooves have
provided a detailed picture of the ligand with which TCRs
interact. Crystal structures of one mouse TCR 
 
b
 
 chain (11),
one mouse TCR V
 
a
 
 domain (12), and two 
 
a
 
/
 
b
 
-TCRs
bound to their class I MHC 
 
1
 
 peptide ligands (13, 14),
verified predictions (15–17) that the ligand binding site of
the TCR consists of Ig-like CDR loops supported by a
dual 
 
b
 
 sheet framework, but has not yet provided enough
information to allow the construction of detailed models of
the CDR loop architecture or the examination of the role
of TCR framework residues in shaping it.
In this paper, we describe a mutation in the NH
 
2
 
-termi-
nal V
 
a
 
 amino acid of a mouse 
 
a
 
/
 
b
 
-TCR that alters its
ability to bind to its MHC 
 
1
 
 peptide ligand. We discuss
how this non-CDR residue may play an important role in
TCR specificity.
  
1920
 
NH
 
2
 
 Terminus of TCR 
 
a
 
 Chain Affects Specificity
 
Materials and Methods
 
Cell Lines.
 
The mouse T cell hybridoma used in these studies
was 2B10.D2O-22.3 (22.3) specific for chicken OVA peptides
323–339 or 327–339 presented by IA
 
d
 
 (IA
 
d
 
/OVA). It was gener-
ated by fusing the AKR thymoma fusion partner BW-1100.
129.237 (BW
 
a
 
2
 
/
 
b
 
2
 
; 18) to lymph node cells from a B10.D2 mouse
immunized with OVA 327–339 (Kushnir, E., unpublished data).
The TCR 
 
a
 
 and 
 
b
 
 chains of 22.3 are identical in amino acid se-
quence to those of DO-11.10, a previously described T cell hy-
bridoma with the same specificity (19, 20). Therefore, these chains
are designated DO
 
a
 
 and DO
 
b
 
 in this paper. Unlike DO-11.10,
however, 22.3 did not express any other functional TCR-
 
a
 
 or -
 
b
 
genes. 22.3 was recloned to isolate two subclones, 22.3.111 and
22.3.145, which bear lower levels of surface TCR. In addition, a
spontaneous TCR 
 
a
 
 chain loss variant of 22.3 was isolated,
22.3
 
a
 
2
 
. This variant expresses DO
 
b
 
 mRNA, but does not con-
tain DNA encoding DO
 
a
 
 and therefore was useful as a recipient
for ( chain transfection studies.
 
Two-color Flow Cytometry.
 
T cell hybridomas were stained for
cell surface molecules and analyzed by flow cytometry as previ-
ously described (21) using the following mAbs: KJ1-26 (22) is
specific for the idiotype of the TCR on DO-11.10 and 22.3, and
H57-597 (23), 145-2C11 (24), and GK1.5 (25) are specific for
mouse TCR C
 
b
 
, CD3
 
e
 
, and CD4, respectively. In brief, 2–5 
 
3
 
10
 
5
 
 hybridoma cells were incubated with biotinylated KJ1-26 or
H57-597 at 4
 
8
 
C for 20 min. Cells were washed three times and
incubated at 4
 
8
 
C for 20 min with FITC-conjugated 145-2C11 or
GK1.5 and streptavidin R–conjugated phycoerythrin (Sigma Chem-
ical Co., St. Louis, MO). Finally, cells were washed three times
and two-color fluorescence data was acquired on either an EPICS
C or a Profile flow cytometer (Coulter Corp., Hialeah, FL).
 
T Cell Hybridoma Stimulation Assays.
 
T cell hybridoma acti-
vation in response to TCR ligation was assayed by measuring IL-2
secretion, as described previously (26). Stimulation assays were
performed in 96-well flat-bottomed microtiter plates. In peptide
stimulations 10
 
5
 
 IA
 
d
 
-expressing A20-1.11/B5 B cell lymphoma cells
(27) were added per well with different concentrations of OVA
327–339. For anti-TCR mAb stimulation, Immulon-3 (Dyna-
tech Labs. Inc., Chantilly, VA) microtiter plates were coated
overnight at 4
 
8
 
C with serial dilutions of protein A–purified KJ1-
26 in PBS. Peptide and antibody stimulations both used 10
 
5
 
 hy-
bridoma T cells/well and were incubated for 16–30 h at 37
 
8
 
C.
IL-2 production was quantitated using the IL-2–dependent cell
line HT-2 (28) and measurement of HT-2 survival by the oxida-
tion of (dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(29).
 
Characterization of the V
 
a
 
13.1 leader from 22.3.
 
Using an an-
chored PCR strategy modified from Loh et al. (30), DNA encod-
ing the V
 
a
 
13.1 (AV13S1) leader was cloned to determine the un-
known sequence of its 5
 
9
 
 end. Total RNA was prepared from the
22.3 hybridoma using the Ultraspec reagent (Biotecx Labs.,
Houston, TX). Oligo-dT-primed first strand cDNA was synthesized
using the SuperScript reverse transcriptase cDNA synthesis kit
(GIBCO BRL, Gaithersburg, MD) and was tailed at the 5
 
9
 
 end
with dG residues using terminal deoxynucleotidyl transferase (In-
ternational Biotechnologies Inc., New Haven, CT). TCR 
 
a
 
chain gene sequences were PCR amplified from tailed cDNA
using the anchored sense primer 5
 
9
 
-ATCGAGTCGACGC-
CCCCCCC-3
 
9
 
 and the antisense primer 5
 
9
 
-CCCCAGACAGC-
CGTCTTGACG-3
 
9
 
, synthesized at the National Jewish Molecu-
lar Resource Center (Denver, CO). The latter primer anneals to
an insertion in the 3
 
9
 
 untranslated region of TCR 
 
a
 
 chain tran-
scripts that is present in C57 mouse strains, but not AKR or
 
BALB/c strains (31, 32, and Seibel, J., unpublished data). This
avoided amplification of the nonfunctional TCR 
 
a
 
 chain tran-
scripts contributed to the 22.3 hybridoma by the AKR thymoma
fusion partner BW
 
a
 
2
 
/
 
b
 
2
 
 (33, 34). This anchored PCR product
was reamplified using the same anchored sense primer and the an-
tisense primer 5
 
9
 
-TCTCGAATTCAGGCAGAGGGTGCTG-
TCC-3
 
9
 
 (35), yielding a product that was digested with SalI and
EcoRI and cloned into the pTZ18R vector (Pharmacia, Piscat-
away, NJ) for sequencing. The complete cDNA sequence of the
V
 
a
 
13.1 leader and its 5
 
9
 
 untranslated region are presented in Fig. 1.
 
DO
 
a
 
 Chain Gene Constructs and Expression Vectors.
 
We used
PCR techniques (36, 37) to construct four versions of the V
 
a
 
 por-
tion of DO
 
a
 
 chain gene using either the V
 
a
 
11.2 (AV11S2) or
V
 
a
 
13.1 (AV13S1) leader peptide and having a predicted NH
 
2
 
-
terminal amino acid of either aspartic acid (D) or glutamic acid (E).
These are designated DO
 
a
 
L11terD, DO
 
a
 
L11terE, DO
 
a
 
L13terD,
and DO(L13terE (identical to wild-type DO
 
a
 
 (Fig. 2). These
were cloned in pTZ18R fused in frame to the mouse C
 
a
 
 gene
using a XhoI site at the 5
 
9
 
-end of the V
 
a
 
 segment and an intro-
duced AccIII site at the 5
 
9
 
-end of C
 
a
 
 (36), such that the final
complete 
 
a chain was flanked by EcoRI sites. To express these
variant DOa constructs in the 22.3a2 hybridoma, the EcoRI
fragments were isolated and cloned into the EcoRI site of the mu-
rine retrovirus–based vector, LXSN (38). Using methods modi-
fied from Miller et al. (38), DOa RNAs were packaged into ret-
roviruses in the GP&env AM12 (39) and PA-317 (40) cell lines,
and were introduced into the 22.3a2 hybridoma by infection.
Infectants with stably integrated DOa genes were selected and
maintained with culture medium containing 1–1.2 mg/ml G418
(Geneticin; GIBCO BRL).
Production of Soluble TCRs and IAd Protein Covalently Bound to
Chicken OVA 327–339. XhoI/AccIII fragments of DOaL11terD
and DOaL13terE were cloned in frame with a truncated gene for
mouse Ca in a previously described baculovirus transfer vector
that also encodes the soluble DO-11.10(D1,3) TCR b chain (36).
Figure 1. Complete nucleotide sequence of the Va13.1 leader and its
59 untranslated region. The sequence of the Va13.1 leader was assembled
from six independently cloned PCR products of different lengths, which
were obtained by anchored reverse transcriptase PCR from the B10.D2-
derived T cell hybridoma, 22.3. Deduced amino acid residues are shown.
Underlined triplets in the 59 untranslated region indicate stop codons,
which are found in all three reading frames. The Va11.2 leader is shown
for comparison. Assignment of the boundary between the leaders and the
mature variable domains is based on standard mouse TCR a chain se-
quence alignments (54).1921 Seibel et al.
Recombinant baculoviruses prepared from these vectors coex-
pressing the TCR-a and -b genes were used to infect Hi 5 in-
sect cells (Invitrogen, San Diego, CA). Soluble heterodimers
were purified from cell supernatants by immunoaffinity chroma-
tography on an antiidiotype column, followed by a HiLoad 26.60
Superdex200 size exclusion column (Pharmacia). The proteins
were further purified to a single detectable species using Mono Q
ion exchange chromatography (Pharmacia). IAd-OVA, a soluble
ligand for the DOa/b-TCR that consists of a soluble IAd mole-
cule genetically attached to the OVA peptide via a flexible pep-
tide linker to the IAdb chain NH2 terminus, was produced in
baculovirus as previously described (41). It was purified by immu-
noaffinity chromatography on an anti-IAd mAb (M5/114, refer-
ence 42) column, and further purified on a HiLoad 26.60 Super-
dex 200 column. Gels revealed that these procedures yielded
preparations of monomeric heterodimers of both the TCR and
class II proteins with no detectable contamination of either pro-
tein with aggregates or homodimers.
BIAcore Measurements of TCR Binding to IAd-OVA. The BIA-
core system was used to assess soluble IAd-OVA binding to
TCRs. The high affinity anti-Cb mAb, H57-597, was immobi-
lized in flow cells of a BIAcore biosensor CM-5 chip using stan-
dard amine coupling chemistry. Flow cells were injected with
solutions of various soluble TCRs at 5 mg/ml until binding to the
anti-Cb antibody was saturated. This captured TCR increased
surface plasmon resonance signals by z2,000 resonance units.
Since the captured TCR dissociated very slowly, we could detect
its binding to subsequently injected IAd-OVA. Solutions of IAd-
OVA (2.5, 5, or 10 mM in phosphate-buffered saline containing 5
mM azide and 0.005% P20 surfactant) were injected for 1 min at
a flow rate of 20 ml/min. The TCR-bound IAd-OVA was then
allowed to dissociate for several minutes. Between injections, the
anti-Cb mAb was resaturated with TCR. To control for signal
due to the bulk refractive index of the IAd-OVA in solution, or
for any differences in the refractive index of the buffers used, an
identical set of injections were performed in a flow cell contain-
ing captured free DOb chain, rather than a/b-TCR. On and off
rates for binding of IAd-OVA were calculated using the BIAcore
software.
Results
Expression of a TCR a Chain in an a Chain–deficient
Mouse T Cell Hybridoma. To study the effects of muta-
tions in the TCR a chain on MHC 1 peptide recognition
by T cells, we used a mouse T cell hybridoma, 22.3, which
could be stimulated by either IAd class II MHC molecules
bound to chicken OVA 327-339 (IAd/OVA) or by the
anti-TCR idiotype mAb, KJ1-26 (22). In an initial experi-
ment, receptor expression in an a loss variant of this hybri-
doma, 22.3a2, was restored by infection with a retrovirus
carrying a version of the full-length Va13.1 bearing DOa
chain gene. This construction, DOaL11terD, differed from
the natural DOa chain in two respects. First, it contained a
Va11.2 leader (L11) in lieu of the then unknown native
Va13.1 leader (L13). Second, after cleavage of its leader
peptide, the mature NH2 terminus of the DOaL11terD
chain was aspartic acid (terD), instead of the glutamic acid
(terE) of wild-type DOa. This conservative substitution was
introduced to maintain a convenient cloning site. It was
not expected to affect TCR specificity, since we had previ-
ously shown that it had no detectable effect on the binding
of a number of anti-TCR mAbs, including KJ1-26, an mAb
specific for the receptor idiotype (Kappler, J., unpublished
data).
The infectants were screened for cell surface TCR ex-
pression by staining with mAbs to the DO TCR idiotype
and CD3e chain. Their levels of idiotype-reactive TCR
were slightly lower than that of the parental hybridoma,
22.3, but were equal to or greater than those on two low
TCR-expressing subclones of 22.3, 22.3.111, and 22.3.145
(Fig. 3). Cell surface levels of CD3e suggested proper TCR
association with CD3 components (data not shown). These
staining results suggested that the DOaL11terD protein
folded properly, associated normally with the TCR b chain
and CD3 components, and reconstituted cell surface TCR
complexes of normal structure.
To determine whether the structural integrity of the
TCR complexes on the infectants was also reflected in
functional competence, the infectants were cultured in
plastic wells coated with antiidiotype mAb. In response to
this TCR ligation and cross-linking stimulus, the infectants
secreted IL-2 in a manner similar to that of the wild-type
Figure 2. DOa chain variant constructs. Circled letters indicate the pre-
dicted NH2-terminal amino acid of the mature a chain.
Figure 3. Infectants bearing the variant TCR a chain DOaL11terD
respond to immobilized antiidiotype mAb as well as the parental hybri-
doma, 22.3, does. 22.3.111 and 22.3.145 are low TCR expressing sub-
clones of 22.3. Data are representative of multiple experiments. TCR
level indicates the mean linear fluorescence of antiidiotype mAb staining
of the hybridomas.1922 NH2 Terminus of TCR a Chain Affects Specificity
hybridoma, 22.3 (Fig. 3). This suggested that the TCR
complexes containing the DOaL11terD chain were suffi-
cient for normal ligation-induced signaling within the T cell
hybridoma.
Replacement of the 22.3 a Chain with the DOaL11TerD
Chain Resulted in a Hybridoma with Dramatically Reduced
Ability to Respond to IAd/OVA. Since DOaL11terD-con-
taining  TCR heterodimers mediated a vigorous IL-2 re-
sponse to anti-TCR antibody stimulation, it was surprising
that they did not reconstitute good IAd/OVA reactivity. As
shown in Fig. 4, DOaL11terD infectants responded much
more poorly to IAd/OVA than did the parental hybridoma,
22.3. Since the TCR a chain in these infectants differed
from that of 22.3 only in its leader peptide and the substitu-
tion of D for E at the mature NH2 terminus, one or both of
these changes must have caused the impaired responsive-
ness. The amino acid sequence of the leader might, for ex-
ample, have altered the site at which the leader is trimmed
from the mature protein. Such an effect has been described
in several proteins (43–47), including an antidigoxin anti-
body in which single substitutions in the heavy chain leader
peptide changed the length of the mature chain by up to 10
residues (48). Some of these length changes were sufficient
to change the affinity of the antibody. An alternative hy-
pothesis was that the NH2 terminus of the TCR chain in-
fluenced directly or indirectly TCR interaction with MHC 1
peptide.
Responsiveness to IAd/OVA Was Restored in Infectants Ex-
pressing TCR a Chains with E at the Predicted NH2 Terminus,
Regardless of Va11.2 or Va13.1 Leader Peptide Usage. To
identify individually the contributions of leader peptide and
NH2 terminus to DOa chain function, we generated four
types of 22.3a2 infectants with each possible combination
of L11, L13, terD, and terE (Fig. 2). The previously un-
characterized L13 leader was cloned from 22.3 (Fig. 1, Ma-
terials and Methods). Infectant clones that expressed com-
parable levels of cell surface TCR were selected by staining
with antiidiotype mAb. Four clones of each type were
Figure 4. Infectants bearing the variant TCR a chain DOaL11terD
respond poorly to IAd/OVA stimulation. cOVA 327–339 peptide was
presented to the hybridomas by the IAd-expressing B cell lymphoma,
A20. Data points indicate the means of duplicate wells in one representa-
tive experiment.
Figure 5. Infectants bearing
any one of four DO TCR a
chain variants respond equally
well to immobilized antiidio-
type mAb. Data points represent
the means of two independent
experiments with duplicate wells.
Error bars indicate standard errors
of the mean. Four infectants of
each variant type were tested.
TCR levels of all infectants var-
ied by less than twofold.1923 Seibel et al.
tested for their ability to respond to antiidiotype antibody
and to IAd/OVA. All four types of infectants possessed
comparable signal transduction capacity, since they pro-
duced similar levels of IL-2 when stimulated with immobi-
lized antiidiotype antibody (Fig. 5). We do not know why
one DO(L13terD infectant responded more poorly than
the other three.
In contrast, the infectants were readily divided into two
groups based on their ability to respond to IAd/OVA (Fig.
6). Regardless of the leader peptide they used, infectants ex-
pressing D at the NH2 terminus of their TCR a chains
(DOaL11terD and DOaL13terD) responded very poorly.
By contrast, infectants expressing NH2-terminal E (DOa
L11terE and DOaL13terE) responded strongly.
The Mature NH2 Termini of Variant DOa Chains Produced
as Soluble Proteins in Baculovirus Were as Predicted. These ex-
periments demonstrated that the leader peptide sequence
did not affect the function of the DOa chain variants, and
highlighted the importance of the predicted NH2 terminus
of the mature protein for IAd/OVA responses. However, it
was still formally possible that the E and D containing a
chains might have had their signal peptides cleaved at dif-
ferent sites. This would have made the two types of chains
different in length. Some structural aspect of the length dis-
parity could have directly affected the interaction of the
TCR with MHC 1 peptide, but not with anti-TCR anti-
bodies.
To test this hypothesis, genes encoding soluble DOa chains
with predicted NH2 termini of either E or D were coex-
pressed in insect cells with a gene encoding a soluble DOb
chain. Purified DOa/b heterodimers were sequenced by
Edman degradation. Both DOa variants were found to
bear the predicted NH2-terminal amino acid, E for DOa-
terE and D for DOaterD. Since insect signal peptidases
typically cleave at the same site as their mammalian coun-
terparts (49), we concluded that TCR a chains in our DOa-
terE and DOaterD infectant hybridomas were identical in
length, differing only in the identity of the amino acid at
their NH2 termini. This difference alone must have been
responsible for their contrasting responses to IAd/OVA.
Substitution of the NH2-terminal Amino Acid of the DOa
Chain Affects the Affinity of the DO TCR for MHC 1 pep-
tide. The simplest explanation for our results was that the
substitution of D for E at the NH2 terminus of DOa di-
rectly altered the ability of the TCR to bind to IAd/OVA.
However, it was also possible that the substitution acted in-
directly. For example, it could have disrupted TCR inter-
actions with a T cell accessory molecule such as CD4. Such
an interaction may not have been required for activation of
the hybridoma during stimulation with antiidiotype anti-
body, where large numbers of TCRs were ligated. How-
ever, it may have been critical for responses to IAd/OVA
stimulation, where only a few TCRs on each hybridoma
were engaged. To distinguish between these mechanisms,
we used surface plasmon resonance to measure directly the
binding of soluble IAd-OVA (40) to DOa/b heterodimers.
Figure 6. Infectants bearing
variant DOa chains with D, but
not E, at their predicted NH2
termini respond poorly to IAd/
OVA. Data points represent the
means of three independent ex-
periments with duplicate wells,
except for those at 250 and 500
mg/ml OVA which represent
only two such experiments. Er-
ror bars indicate standard errors
of the mean. Four infectants of
each type were tested. TCR lev-
els of all infectants varied by less
than twofold.1924 NH2 Terminus of TCR a Chain Affects Specificity
Anti-Cb mAb was used to immobilize DOa/b hetero-
dimers containing either DOaterE or DOaterD chains in
separate flow cells of a biosensor chip. A flow cell in which
the free DOb chain was immobilized was used as a nega-
tive control. Various concentrations of IAd-OVA were
passed through the flow cells and the binding kinetics
followed (Fig. 7). Obvious binding of IAd-OVA to a TCR
containing DOaterE was seen at all class II concentrations.
The interaction had a relatively slow on rate, ka 5 1.60 3
103 M21s21, and a fast off rate, kd 5 0.05s21, resulting in
a dissociation constant (KD) of 31 mM. These kinetic and
thermodynamic constants are similar to those observed for
other TCRs binding to MHC class II 1 antigen complexes
(50). In contrast, IAd-OVA bound very poorly to a TCR
containing DOaterD. Very weak specific binding detected
only at the highest concentration of IAd-OVA. This sug-
gested a dissociation constant .300 mM. The results showed
that the NH2 terminal E to D substitution in DOa dis-
rupted TCR binding to class II 1 peptide in the absence
of accessory molecules. We concluded that N terminal E
must play a direct role in the interaction of this TCR with
IAd/OVA.
Discussion
We have demonstrated that an E to D change in the
NH2-terminal amino acid of a mouse TCR a chain signif-
icantly altered the affinity of the a/b-TCR heterodimer
for its MHC 1 peptide ligand. This conservative change
simply shortened the amino acid side chain by a single me-
thylene group without changing its negative charge. This
effect did not result in a gross alteration in TCR structure,
since detection of the TCR complexes by anti-TCR mAbs
was unaffected by the substitution. Moreover, overall TCR-
mediated signal transduction was not impaired by the sub-
stitution, since hybridomas bearing it responded normally
to TCR cross-linking by immobilized antiidiotypic mAb.
The E to D substitution could have affected MHC 1
peptide responsiveness either directly, by disrupting a con-
tact between this amino acid and the ligand, or indirectly,
by altering the shape or position of amino acids on one of
the receptor CDR loops. The recent crystal structures of
TCR Vas both free and as part of TCR 1 MHC com-
plexes suggest that either of these possibilities is feasible
(Fig. 8, references 12–14). These structures include a free
Va domain, mouse Va4(AV4S1), and two TCRs bound
to their MHC class I/peptide ligands. These latter TCRs
contained mouse Va3 (AV3S1) and human Va2(AV2S1).
In all three structures, the Va NH2-terminal amino acid
is solvent exposed and in contact with the Va b strands
preceding Va CDR1 and following Va CDR3. It is easily
conceivable that a mutation in this amino acid could alter
CDR1 or CDR3 conformation. This is particularly evi-
dent in the mouse Va4 structure (12), where the side chain
carbonyl group of the NH2-terminal aspartic acid interacts
intimately with both b strands.
Support for this notion comes from the study of Ig struc-
tures. One study comparing Ig crystal structures concluded
that the conformation and position of CDR2 of the Ig
heavy chain is largely shaped by the nature of the side chain
on framework residue 71 (2). In another study, a spontane-
ous variant of an antidigoxin antibody with 580-fold less
affinity for digoxin than wild type was found to have a sub-
stitution from S to R at position 94 in its heavy chain, a
residue predicted to lie in the framework at the base of
CDR3 (48, 51–53). Computer modeling suggested that the
substitution increased hydrogen bonding between CDR3
of the heavy chain and CDR2 of the light chain so that the
digoxin binding surface of the Ig was altered. Interestingly,
most of the substitution’s effect was reversed if two residues
from the NH2 terminus of the heavy chain were removed.
Modeling suggested that the deletion increased the solvent
accessibility of R94, destabilizing the aberrant hydrogen
bonding and returning the CDR loop structures to wild
type.
Figure 7. Substitution of D for E at the DOa chain NH2 terminus
lowers the affinity of cell-free a/b-TCR for IAd-OVA. Various concen-
trations of IAd-OVA were injected in flow cells with immobilized DOa/b
TCRs bearing DOa chains with either D or E at the NH2 terminus as
described in the Materials and Methods. A flow cell with immobilized
free b chain from this receptor was used as a control for signal from pro-
tein in solution and buffer differences.
Figure 8. Position of the Va NH2 terminus in three TCR crystal
structures. The program Molscript was used to create a ribbon representa-
tion of three Va elements based on their crystal structures. In each case, a
wire frame representation of the NH2-terminal amino acid is shown. The
mouse Va4 structure (12) was of a Va dimer in the absence of Vb. The
mouse Va3 (13) and human Va2 (14) structures were of complete a/b-
TCRs. The views are of the Vas with their solvent exposed faces toward
and their Vb interaction surfaces facing away from the reader.1925 Seibel et al.
In the two TCR 1 MHC class I crystal structures, the
side chain of the Va NH2-terminal amino acid does not
appear to make direct contacts with the MHC ligand and,
in fact, the side chain of the NH2-terminal lysine of human
Va2 appears disordered in the structure (14). However, the
free NH2-terminal amino group of the Va2 chain itself is
connected by a salt bridge to a conserved glutamic acid in
the a helical region of the MHC class I a1 domain (14).
Such a salt bridge is not found in the TCR 1 MHC class I
structure containing mouse Va3 (13), and probably cannot
be a general feature of TCR 1 MHC class II complexes
since class II lacks the conserved glutamic acid residue in
the a helix of its a1 domain. However, the overall posi-
tions of the Va NH2-termini in the crystals suggest that de-
pending on the exact orientation and pitch of the TCR on
its MHC ligand, direct interaction between the Va NH2-
terminal amino acid side chain and the MHC ligand may
not be an infrequent feature of the complex.
Although further work will be necessary to confirm the
generality of our results with this particular a/b-TCR, our
findings suggest that gene constructs used to express soluble
TCRs for use in binding assays and x-ray crystallography
must be designed carefully. Substitutions at non-CDR resi-
dues must be introduced with the knowledge that they
have the potential to disrupt MHC 1 peptide recognition.
A detailed understanding of the role of TCR framework
residues in MHC 1 peptide recognition will be difficult to
attain until numerous TCR and TCR 1 MHC 1 peptide
crystal structures have been solved.
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